Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 2, 2009, Pages 136-143

  Stirban, Alin ^a   Laude, Dominique ^b   Elghozi, Jean Luc ^b   Sander, Denise ^c   Agelink, Marcus W ^d,e   Hilz, Max J ^f,g   Ziegler, Dan ^c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e Klinikum Herford   (Germany)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g NEW YORK UNIVERSITY   (United States)

Author keywords

Autonomic; Baroreceptors; Diabetes; Endothelium; Nervous system; Sildenafil

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PLACEBO; SILDENAFIL; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; VASODILATOR AGENT;

ADULT; ARTERY DILATATION; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE REGULATION; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG MECHANISM; ERECTILE DYSFUNCTION; FLUSHING; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; ORTHOSTATIC BLOOD PRESSURE; PARASYMPATHETIC FUNCTION; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SUPINE POSITION; SYMPATHETIC FUNCTION; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; BLOOD PRESSURE; BODY POSTURE; BRACHIAL ARTERY; CARDIOVASCULAR SYSTEM; DRUG EFFECT; HEART RATE; HISTOLOGY; INNERVATION; PATHOPHYSIOLOGY; PATIENT SELECTION; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

AUTONOMIC NERVOUS SYSTEM; BAROREFLEX; BLOOD PRESSURE; BRACHIAL ARTERY; CARDIOVASCULAR SYSTEM; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; ERECTILE DYSFUNCTION; HEART RATE; HUMANS; MALE; PATIENT SELECTION; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PLACEBOS; POSTURE; PULSE; PURINES; SULFONES; VASODILATION; VASODILATOR AGENTS;

EID: 65549092581     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.921     Document Type: Article

References (56)

1. Guay AT. Relation of endothelial cell function to erectile dysfunction: implications for treatment. Am J Cardiol 2005; 96(12): 52M-56M.
2. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43(2): 179-184.
3. Palumbo PJ. Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. Am J Med Sci 2007; 334(6): 466-480.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362(6423): 801-809.
5. Guerci B, Kearney-Schwartz A, Bohme P, Zannad F, Drouin P. Endothelial dysfunction and Type 2 diabetes. Part 1: physiology and methods for exploring the endothelial function. Diabetes Metab 2001; 27(4): 425-434.
6. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002; 25(8): 1336-1339.
7. Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001; 44(10): 1296-1301.
8. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5(8): 689-702.
9. Kimura M, Higashi Y, Hara K, et al. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension 2003; 41(5): 1106-1110.
10. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute Type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36(3): 845-851.
11. Halcox JP, Nour KR, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40(7): 1232-1240.
12. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47(2): 214-220.
13. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a Pilot Study. Int J Impot Res 2007; 19(2): 200-207.
14. Mazo EB, Gamidov SI, Iremashvili VV. Does the clinical efficacy of vardenafil correlate with its effect on the endothelial function of cavernosal arteries? A Pilot Study. BJU Int 2006; 98(5): 1054-1058.
15. Dishy V, Sofowora G, Harris PA, et al. The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clin Pharmacol Ther 2001; 70(3): 270-279.
16. Dishy V, Harris PA, Pierce R, et al. Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. Br J Clin Pharmacol 2004; 57(2): 209-212.
17. Robinson SD, Ludlam CA, Boon NA, Newby DE. Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. Heart 2005; 92(2): 170-176.
18. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001; 22(1): 36-52.
19. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115(3): 387-397.
20. Food and Drug Administration (Center for Drug Evaluation and Reseach). 1998; Summary of Death Reports in Viagra Received From Marketing (Late March) Through June 1998. Washington, DC.
21. Arora RR, Timoney M, Melilli L. Acute myocardial infarction after the use of sildenafil. N Engl J Med 1999; 341(9): 700-700.
22. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342(22): 1622-1626.
23. Piccirillo G, Nocco M, Lionetti M, et al. Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. Am Heart J 2002; 143(4): 703-710.
24. Fazan R Jr, Huber DA, Silva CA, Dias dSV, Salgado MC, Salgado HC. Sildenafil acts on the central nervous system increasing sympathetic activity. J Appl Physiol 2008; 104(6): 1683-1689.
25. Schalcher C, Schad K, Brunner-La Rocca HP, et al. Interaction of sildenafil with CAMP-mediated vasodilation in vivo. Hypertension 2002; 40(5): 763-767.
26. Phillips BG, Kato M, Pesek CA, et al. Sympathetic activation by sildenafil. Circulation 2000; 102(25): 3068-3073.
27. Agelink MW, Schmitz T, Rembrink K, et al. Cardiovascular effects of sildenafil citrate (Viagra): a naturalistic cross-over study. Eur J Med Res 2001; 6(11): 459-464.
28. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229-234.
29. Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29(9): 2064-2071.
30. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-Invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340(8828): 1111-1115.
31. Agelink MW, Malessa R, Baumann B, et al. Standardized tests of heart rate variability: normal ranges obtained from 309 healthy humans, and effects of age, gender, and heart rate 1. Clin Auton Res 2001; 11(2): 99-108.
32. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93(5): 1043-1065.
33. Tulppo MP, Kiviniemi AM, Hautala AJ, et al. Physiological background of the loss of fractal heart rate dynamics. Circulation 2005; 112(3): 314-319.
34. Ziegler D, Laux G, Dannehl K, et al. Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med 1992; 9(2): 166-175.
35. Ziegler D, Laude D, Akila F, Elghozi JL. Time- and frequency-domain estimation of early diabetic cardiovascular autonomic neuropathy. Clin Auton Res 2001; 11(6): 369-376.
36. Pagani M, Lombardi F, Guzzetti S, et al. Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog. Circ Res 1986; 59(2): 178-193.
37. Robbe HW, Mulder LJ, Ruddel H, Langewitz WA, Veldman JB, Mulder G. Assessment of baroreceptor reflex sensitivity bymeans of spectral analysis. Hypertension 1987; 10(5): 538-543.
38. Bertinieri G, Di RM, Cavallazzi A, Ferrari AU, Pedotti A, Mancia G. Evaluation of baroreceptor reflex by blood pressure monitoring in unanesthetized cats. Am J Physiol 1988; 254(2): H377-H383.
39. Parati G, Frattola A, Di RM, Castiglioni P, Pedotti A, Mancia G. Effects of aging on 24-h dynamic baroreceptor control of heart rate in ambulant subjects. Am J Physiol 1995; 268(4): H1606-H1612.
40. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11(6): 319-326.
41. Vardi Y, Klein L, Nassar S, Sprecher E, Gruenwald I. Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. Urology 2002; 59(5): 747-752.
42. Mahmud A, Hennessy M, Feely J. Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J Hum Hypertens 2001; 15(10): 707-713.
43. Zusman RM, Prisant LM, BrownMJ. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. J Hypertens 2000; 18(12): 1865-1869.
44. Pomara G, Morelli G, Pomara S, et al. Cardiovascular parameter changes in patients with erectile dysfunction using Pde-5 inhibitors: a study with sildenafil and vardenafil. J Androl 2004; 25(4): 625-629.
45. Zusman RM. Cardiovascular data on sildenafil citrate: introduction. Am J Cardiol 1999; 83(5A): 1C-2C.
46. Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83(5A): 29C-34C.
47. Foresta C, Ferlin A, De TL, et al. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 2006; 18(5): 484-488.
48. Vlachopoulos C, Tsekoura D, Alexopoulos N, Panagiotakos D, Aznaouridis K, Stefanadis C. Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. Am J Hypertens 2004; 17(11): 1040-1044.
49. Hryniewicz K, Dimayuga C, Hudaihed A, et al. Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci (Lond) 2005; 108(4): 331-338.
50. Saka B, Oflaz H, Erten N, et al. Non-invasive evaluation of endothelial function in hypertensive elderly patients. Arch Gerontol Geriatr 2005; 40(1): 61-71.
51. Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004; 21(2): 171-175.
52. Fonseca V, Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments? Am J Cardiol 2005; 96(12): 13M-18M.
53. Aversa A, Vitale C, Volterrani M, et al. Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med 2008; 25(1): 37-44.
54. Dietz U, Tries HP, Merkle W, Jaursch-Hancke C, Lambertz H. Sildenafil does not change coronary flow reserve in diabetics with erectile dysfunction. Dtsch Med Wochenschr 2003; 128(5): 190-195.
55. Sloan RP, Shapiro PA, Bagiella E, Bigger JT Jr, Lo ES, Gorman JM. Relationships between circulating catecholamines and low frequency heart period variability as indices of cardiac sympathetic activity during mental stress. Psychosom Med 1996; 58(1): 25-31.
56. Lipsitz LA, Ryan SM, Parker JA, Freeman R, Wei JY, Goldberger AL. Hemodynamic and autonomic nervous system responses to mixed meal ingestion in healthy young and old subjects and dysautonomic patients with postprandial hypotension. Circulation 1993; 87(2): 391-400.